Reckitt Benckiser Signs $482 Million Pact With Bristol-Myers

Reckitt Benckiser Plc, the maker of Nurofen painkillers, entered a $482 million deal with pharmaceutical maker Bristol-Myers Squibb Co. to license a number of Latin American over-the-counter healthcare remedies as it expands its presence in emerging markets.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.